<DOC>
	<DOCNO>NCT01707472</DOCNO>
	<brief_summary>This open label , exploratory study simtuzumab ( GS-6624 ) adult infect HIV , hepatitis C virus ( HCV ) , co-HIV/HCV histological evidence liver fibrosis . Participants receive simtuzumab 700 mg intravenously every 2 week total 24 week ( 12 infusion ) continue standard therapy HIV ( HIV-infected subject ) .</brief_summary>
	<brief_title>A Phase 2a Study Simtuzumab HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key HIVinfected subject must positive serology viral load suppress 400 copies/mL HCVinfected subject must : Chronic HCV infection HCV RNA ≥ 2000 IU/ml AND least 1 follow : Been null responder previous pegylated interferon ribavirin therapy OR Failed achieve sustain virologic response ( SVR ) regimen contain directacting antiviral ( DAA ) addition pegylated interferon ribavirin OR Are unwilling receive contraindication interferon therapy HCV HIV/HCV coinfected subject must : Positive HIV serology viral load suppress 400 copies/mL Chronic HCV infection HCV RNA ≥ 2000 IU/ml AND least 1 follow : Been null responder previous pegylated interferon ribavirin therapy OR Failed achieve SVR regimen contain directacting antiviral ( DAA ) addition pegylated interferon ribavirin OR Are unwilling receive contraindication interferon therapy HCV Willing allow blood tissue sample store future use study HIV infection , immune function , liver disease additional mechanism involve liver fibrosis among patient HIV and/or HCV , may relate directly specific objective study protocol Have primary care physician Key Cause liver fibrosis HCV longterm ART treatment HIV Currently treat HCV Evidence active Hepatitis A , B D infection History evidence hepatocellular carcinoma Unwillingness undergo liver biopsy pretreatment posttreatment , undergo protocol require tests/procedures return site require visit Presence contraindication magnetic resonance imaging ( e.g. , presence metal body , cardiac neural pacemaker , aneurysm clip , cochlear implant , claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Liver Fibrosis</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>GS-6624</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>